

***NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES  
OR DISSEMINATION IN THE UNITED STATES***



**Abba Medix Corp. Experiencing Rapid Patient Growth, Surpassing 100 Registered Patients since November 2019**

*Toronto – January 27, 2020 (CNW)* - Canada House Wellness Group Inc. (CSE: CHV) (“**Canada House**” or the “**Company**”), is pleased to announce that its wholly owned subsidiary, Abba Medix Corp. (“**Abba**”), has now registered its 100<sup>th</sup> medical patient in less than three months. This news comes on the heels of Abba’s January 22, 2020 announcement that it has added three additional strains to its product portfolio and now has a total of four strains available for sale to registered Abba patients. Abba anticipates its patient growth rates will rise sharply as awareness of Abba’s excellent variety of dried flower spreads throughout the Canadian medical cannabis landscape, and more specifically to veteran medical patients.

“A key strategy of Canada House is to increase Abba’s patient base by expanding relationships with users of medical cannabis and cannabis clinics across the country,” says Canada House CEO Chris Churchill-Smith. “In addition, we have listened to our patients and have increased the selection of cannabis products to meet their needs. This important milestone drives Canada House and Abba revenues and demonstrates progress on Canada House’s Path to Profitability.”

“Registering Abba’s 100<sup>th</sup> medical patient is an important milestone for our organization and is emblematic of our dedication to medical cannabis patients. We are committed to offering high quality strains that best serve those medical patients looking for solutions to a variety of health and wellness needs and as Abba’s patient base continues to grow, we will strategically and selectively add complementary strains that our patients covet,” said Michael Orrbrooke, Abba’s President and the Chief Revenue Officer of Canada House. “In addition to offering a more comprehensive selection of strains, we intend to offer our products in new

formats to provide our medical patients with many options while maintaining our industry leading customer service and online customer experience.”

### **About Canada House Wellness Group Inc.**

Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.

Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit [www.canadahouse.ca](http://www.canadahouse.ca).

### **For further information, please contact:**

#### **Steven Pearce, Vice-President, Legal**

Canada House Wellness Group Inc.  
289-980-3584  
[spearce@canadahouse.ca](mailto:spearce@canadahouse.ca)

*Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.*

*Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.*